Table 1 Baseline characteristics of the population
Population | Total n = 1315 | Clinical n = 729 | Surgical n = 586 | p -value |
|---|---|---|---|---|
Age (years)* | 61.5 (18.7%) | 64.5 (18.7%) | 57.8 (17.9%) | < 0.001 |
Male gender N (%)** | 677 (51.5%, 49-54) | 384 (52.7%) 49-56) | 293 (50.0%) (46-54) | NS |
Risk factors n (%) | ||||
Prolonged rest or lower limb paralysis | 483 (36.7%) (34-39) | 330 (45.3%) 42-49 | 153 (26.1%) (23-30) | < 0.001 |
Active cancer and/or chemotherapy treatment | 272 (20.7%) (18-23) | 159 (21.8%) (19-25) | 113 (19.3%) 16-22 | NS |
Overweight (BMI > 25) | 267 (20.3%) (18-22) | 330 (45.3%) (17-23) | 123 (21%) (18-24) | NS |
Varicose veins or chronic venous insufficiency | 112 (8.5%) (7-.1) | 68 (9.3%) (7-11) | 44 (7.5%) (5-10) | NS |
Heart failure | 111 (8.4%) (7-10) | 85 (11.7%) (9-14) | 26 (4.4%) (3-6) | < 0.001 |
Central venous catheter | 116 (8.4%) (7-10) | 61 (8.4%) (63-10) | 55 (9.4%) (7-12) | NS |
Chronic obstructive pulmonary disease | 78 (5.9%) (5-7) | 61 (8.4%) (6-10) | 17 (2.9%) (2-4) | <0.001 |
History of DVT/PE | 27 (2.1%) (1-3) | 21 (2.9%) (2-4) | 6 (1.0%) (2-2) | 0.018 |
Myeloproliferative syndrome | 18 (1.4%) 7-2) | 17 (2.3%) (1-3) | 1 (0.2%) (2-5) | < 0.001 |
Inflammatory disease | 15 (1.1%) (0.57-1.7) | 11 (1.5%) (1-2) | 4 (0.7%) (0.1-1.3) | NS |
Estrogen therapy | 14 (1.1%) 0.5-1.6 | 7 (1%) (0.2-2) | 7 (1.2%) (0.32) | NS |
Nephrotic syndrome | 12 (0.9%) (0.4-1.4) | 10 (1.4%) (1-2) | 2 (0.3%) (0.1-0.8) | NS |
Thrombophilia | 5 (0.4%) 0.05-0.7 | 3 (0.4%) (0.1-0.9) | 2 (0.3%) (0.13-0.8) | NS |